Atlas Trials

Azafaros B.V.

7 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Azafaros B.V.

RecordFirmDate
Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3) (NCT07715084)Azafaros B.V.2026-09-28
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease (NCT07399704)Azafaros B.V.2026-02-04
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis (NCT07054515)Azafaros B.V.2025-06-30
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis (NCT07082543)Azafaros B.V.2025-06-30
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC) (NCT07082725)Azafaros B.V.2025-06-30
Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease (NCT05758922)Azafaros B.V.2023-04-24
GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO) (NCT05109793)Azafaros B.V.2022-02-22

Track Azafaros B.V. automatically

Every clearance here is in the API, with alerts when new ones post.